Drug profile · INN
dopamine hydrochloride
NEOATRICON
dopamine hydrochloride (NEOATRICON) is a beta-1 adrenergic receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — dopamine hydrochloride
- US status
- approved
- Class
- Cardiovascular system (C01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
dopamine hydrochloride (NEOATRICON) is a beta-1 adrenergic receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-1 adrenergic receptor agonist
Primary target: Beta-1 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dopamine hydrochloride?
dopamine hydrochloride (NEOATRICON) is a beta-1 adrenergic receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for dopamine hydrochloride?
NEOATRICON is a marketed brand name for dopamine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dopamine hydrochloride?
dopamine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.